Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 1014-1023, December 2009

Surgical management of congenital dermatofibrosarcoma protuberans

  • W. Elliot Love, DO

      Affiliations

    • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Susan A. Keiler, MD

      Affiliations

    • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Joan E. Tamburro, DO

      Affiliations

    • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Kord Honda, MD

      Affiliations

    • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Arun K. Gosain, MD

      Affiliations

    • Department of Plastic Surgery, Rainbow Babies and Children's Hospital, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Jeremy S. Bordeaux, MD, MPH

      Affiliations

    • Department of Dermatology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Case Western Reserve University School of Medicine, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: Jeremy S. Bordeaux, MD, MPH, Department of Dermatology, University Hospitals Case Medical Center, 11100 Euclid Ave, Lakeside 3500, Cleveland, OH 44124.

Congenital dermatofibrosarcoma protuberans (DFSP) is a rare tumor with varying clinical presentations that is commonly misdiagnosed. Treatment of congenital DFSP is complicated by delays in diagnosis and its propensity for subclinical spread. Of 61 reported cases, 11 (18%) were treated with Mohs micrographic surgery (MMS) and 46 (75%) were treated with wide local excision (WLE). One case was treated with imatinib, and the remaining 3 did not differentiate between receiving MMS or WLE. In the cases of congenital DFSP treated with MMS the clearance rate was 100% with an average follow-up of 4.3 years. The clearance rate seen with WLE was 89% with an average follow-up period of 1.9 years. The average margins taken during MMS (1.7 cm) were smaller than those taken with WLE (2.8 cm). Fifty percent of cases with available follow-up undergoing WLE required multiple surgeries. Based on superior cure rates with long-term follow-up, smaller surgical margins, and fewer surgical sessions, MMS should be considered as first-line treatment for congenital DFSP.

Key words: congenital dermatofibrosarcoma protuberans, Mohs micrographic surgery

Abbreviations used: DFSP, dermatofibrosarcoma protuberans, MMS, Mohs micrographic surgery, PDGFB, platelet-derived growth factor β, WLE, wide local excision

 

 Funding sources: Dr Bordeaux is supported by the Dermatology Foundation Clinical Career Development Award in Dermatologic Surgery.

 Conflicts of interest: None declared.

PII: S0190-9622(09)00672-0

doi:10.1016/j.jaad.2009.05.028

Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 1014-1023, December 2009